MedTrace Logo

Gemcitabine and Nabpaclitaxel in Metastatic Pancreatic Carcinoma.

NCT03620461 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 210

Last updated 2018-08-08

No results posted yet for this study

Summary

Retrospective, multicenter study including pts with metastatic pancreatic cancer who started first-line treatment with napaclitaxel plus Gemcitabine between December 2013 and June 2015 according to the routine practice. Overall survival (OS) and progression-free survival (PFS) were assessed for the total sample and the exploratory subgroups based on treatment and clinical characteristics of the study pts.

Conditions

Interventions

DRUG

Gemcitabine - nabpaclitaxel

efficacy and safety

Sponsors & Collaborators

  • Galician Research Group on Digestive Tumors

    lead OTHER

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2013-12-01
Primary Completion
2013-12-01
Completion
2015-06-30

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03620461 on ClinicalTrials.gov